ESMO Immuno-Oncology 2022

ESMO Immuno-Oncology 2022
07–09 December 2022 | Geneva, Switzerland
From the basics of immunotherapies to the latest research results; from understanding different treatment options to the management of toxicities and interpretation of new data, the ESMO Immuno-Oncology Congress will cater to the diverse needs of oncology stakeholders with an interest in this topical field of cancer treatment.

ESMO Immuno-Oncology 2022

ESMO Immuno-Oncology 2022
07–09 December 2022 | Geneva, Switzerland
From the basics of immunotherapies to the latest research results; from understanding different treatment options to the management of toxicities and interpretation of new data, the ESMO Immuno-Oncology Congress will cater to the diverse needs of oncology stakeholders with an interest in this topical field of cancer treatment.
What does the future hold for cellular therapies in solid tumors? 2:37
What does the future hold for cellular therapies in solid tumors?
Michael Nishimura • 28 Nov 2022
Optimizing neoadjuvant therapy in NSCLC with biomarker research 1:24
Optimizing neoadjuvant therapy in NSCLC with biomarker research
Si-Yang Liu • 14 Dec 2022
Elucidating novel targets in NSCLC 1:18
Elucidating novel targets in NSCLC
Si-Yang Liu • 14 Dec 2022
Future directions in lung cancer immunology research 4:27
Future directions in lung cancer immunology research
James Reading • 15 Dec 2022
DONIMI: neoadjuvant domatinostat in patients with melanoma based on IFN-γ signatures 3:19
DONIMI: neoadjuvant domatinostat in patients with melanoma based on IFN-γ signatures
Irene Reijers • 30 Nov 2022
OpACIN-neo: TMB and IFN-γ identified as biomarkers of pathologic response in melanoma 2:53
OpACIN-neo: TMB and IFN-γ identified as biomarkers of pathologic response in melanoma
Irene Reijers • 30 Nov 2022
Improving outcomes in NSCLC with perioperative targeted therapies 2:03
Improving outcomes in NSCLC with perioperative targeted therapies
Si-Yang Liu • 14 Dec 2022
Neoadjuvant nivolumab with or without chemotherapy in resectable NSCLC 2:39
Neoadjuvant nivolumab with or without chemotherapy in resectable NSCLC
Si-Yang Liu • 14 Dec 2022
Key cellular therapy updates in melanoma 2:27
Key cellular therapy updates in melanoma
Omid Hamid • 29 Dec 2022
Advances in utilizing neoadjuvant immunotherapy in melanoma 3:09
Advances in utilizing neoadjuvant immunotherapy in melanoma
Omid Hamid • 29 Nov 2022
Developing a FOXC1-based immunohistochemistry assay for basal-like breast cancer 2:19
Developing a FOXC1-based immunohistochemistry assay for basal-like breast cancer
Partha Ray • 14 Dec 2022
The role of immunohistochemistry in assessing ICI efficacy 3:19
The role of immunohistochemistry in assessing ICI efficacy
Partha Ray • 14 Dec 2022
FOXC1 as a novel prognostic biomarker in immune checkpoint inhibitor therapy 3:39
FOXC1 as a novel prognostic biomarker in immune checkpoint inhibitor therapy
Partha Ray • 14 Dec 2022
What role will TILs play in treating patients with melanoma? 0:50
What role will TILs play in treating patients with melanoma?
Maartje Rohaan • 29 Nov 2022
The impact of metastasectomy in patients with melanoma receiving TILs 3:00
The impact of metastasectomy in patients with melanoma receiving TILs
Maartje Rohaan • 29 Nov 2022
Modulating the tumor microenvironment to enhance cancer vaccines 1:50
Modulating the tumor microenvironment to enhance cancer vaccines
Michael Nishimura • 28 Nov 2022
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals